相关实验视频

Updated: Jun 13, 2025

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

在venetoclax后急性髓性白血病的复发和耐药性:改善二线治疗和组合疗法

Rabia Shahswar¹, Arnold Ganser¹

¹Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany.

Expert review of hematology

|September 9, 2024

概括

威尼托克拉克斯与阿扎西提丁结合是急性髓性白血病 (AML) 的标准,不适合化疗. 克服venetoclax耐药性的策略至关重要,因为治疗后复发仍然是一个重大问题.

科学领域:

血液学血液学血液学
在瘤学瘤学.
药理学药理学是指药理学的学科.

背景情况:

威尼托克拉克斯 (BCL-2 抑制剂) 与阿扎西提丁结合,是急性髓性白血病 (AML) 患者不适合进行密集化疗的标准护理.
基于Venetoclax的方案越来越多地用于AML的前线和救援设置.
基于venetoclax的疗法后的耐药性和复发是严重的担忧,治疗失败后的结果很差.

研究的目的:

总结目前基于venetoclax的AML治疗方法的现状.
审查抗BCL-2抑制的抵抗机制.
讨论在AML中克服venetoclax耐药性的策略.

主要方法:

在PubMed的综合文献搜索 (至2024年4月).
对治疗AML的venetoclax联合治疗的研究的评估.
对venetoclax的反应和耐药性的标志物的研究.

主要成果:

基于Venetoclax的疗法改善了AML的治疗结果.
已经确定了对venetoclax产生初级和二级耐药性的机制.
包括新药在内的组合策略正在被探索以克服耐药性.

结论:

威尼托克拉克斯正在改变AML治疗方法,但耐药性仍然是一个挑战.
克服耐药性的策略是一个未满足的临床需求.
对新型组合的进一步研究对于改善复发性/耐药性AML的结果至关重要.

关键词:

急性骨髓性白血病 (AML) 是一种急性骨髓性白血病.综合向性疗法联合向性疗法低甲化剂是一种低甲化剂.电阻的阻力可以维尼托克莱克斯 (Venetoclax) 是一个

更多相关视频

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

相关概念视频

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Retrovirus Life Cycles

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...